Senores Pharmaceuticals' Q3 FY 2025-26 Quarterly Results
- 22h ago
Result Summary
- Senores Pharmaceuticals Ltd reported a 6.7% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 64.9%.
- Its expenses for the quarter were up by 5.7% QoQ and 52.5% YoY.
- The net profit increased 11.5% QoQ and increased 104.4% YoY.
- The earnings per share (EPS) of Senores Pharmaceuticals Ltd stood at 7.29 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 178.34 | 167.17 | 108.18 | 6.7% | 64.9% |
Total Expenses | 133.74 | 126.54 | 87.69 | 5.7% | 52.5% |
Profit Before Tax | 44.60 | 40.63 | 20.49 | 9.8% | 117.7% |
Tax | 11.02 | 10.51 | 4.06 | 4.9% | 171.4% |
Profit After Tax | 33.58 | 30.12 | 16.43 | 11.5% | 104.4% |
Earnings Per Share | 7.29 | 6.54 | 5.04 | 11.5% | 44.6% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Senores Pharmaceuticals Ltd is a company that operates within the pharmaceutical industry. Its main products and services include the manufacturing and distribution of pharmaceutical drugs and related healthcare products. While detailed information about recent major developments is not available within the provided data, the company is likely involved in the dynamic and competitive landscape of pharmaceutical manufacturing and distribution. This industry is characterized by rigorous regulatory frameworks, significant research and development activities, and a focus on innovation to deliver effective medical solutions.
Revenue
In the third quarter of the fiscal year 2026, Senores Pharmaceuticals Ltd reported a total income of ₹178.34 crores. This represents a quarter-over-quarter increase of 6.7% from ₹167.17 crores in Q2FY26 and a significant year-over-year growth of 64.9% from ₹108.18 crores in Q3FY25. The considerable growth in revenue over the year indicates a robust expansion in the company's income streams, possibly driven by increased sales volume or higher pricing strategies. The sequential quarterly growth also suggests consistent performance improvement during the fiscal year.
Profitability
The profitability of Senores Pharmaceuticals Ltd in Q3FY26 is highlighted by a profit before tax of ₹44.60 crores, marking a QoQ increase of 9.8% from ₹40.63 crores in Q2FY26 and a YoY rise of 117.7% from ₹20.49 crores in Q3FY25. After accounting for taxes of ₹11.02 crores, the company achieved a profit after tax of ₹33.58 crores, which is 11.5% higher than the previous quarter's ₹30.12 crores, and 104.4% higher than the ₹16.43 crores recorded in the same quarter last year. The company's earnings per share for Q3FY26 stood at ₹7.29, exhibiting growth rates parallel to the profit after tax, with both QoQ and YoY increases of 11.5% and 44.6%, respectively.
Operating Metrics
The total expenses for Senores Pharmaceuticals Ltd in Q3FY26 were ₹133.74 crores, showing a 5.7% increase from ₹126.54 crores in Q2FY26 and a 52.5% increase from ₹87.69 crores in Q3FY25. The growth in expenses is aligned with the revenue increase, suggesting operational scaling or cost adjustments. The tax expense for the quarter was ₹11.02 crores, which rose by 4.9% QoQ and 171.4% YoY, reflecting the company's higher taxable income due to increased profitability. The financial data outlines a consistent upward trajectory in both income and expenses, indicating that the company is managing its operational scale effectively while achieving significant profit growth.